Category: Debates & Comparisons
Not all ashwagandha is the same product. KSM-66, Sensoril and Shoden are three branded extracts, standardised to different withanolide levels from different plant parts, and studied for different purposes. Here is the honest breakdown of what separates them.
Category: Debates and Comparisons | Reading time: ~13 min | Level: Intermediate
Two tubs of ashwagandha can sit next to each other, both say "clinically studied" on the label, and contain genuinely different products. One is root-only and standardised to about 5% withanolides. Another packs both root and leaf and is standardised twice as high. A third delivers its active compounds in a capsule a fraction of the size, because it is concentrated to a level the other two do not reach. They are all ashwagandha. They are not the same thing, and the trials that back one do not automatically transfer to another.
This is the part of the ashwagandha story that marketing tends to blur. The herb''s reputation rests on a specific body of clinical trials, and almost all of those trials used a named, branded extract at a named dose. KSM-66, Sensoril and Shoden are the three names that dominate. Knowing what separates them is the difference between buying the product the evidence actually studied and buying a lookalike that happens to share a plant.
So this is a comparison of manufacturing and evidence, not of magic. What is each extract, what has each been studied for, and how should you choose between them without falling for the highest number on the label.
Ashwagandha''s activity comes largely from its withanolides, steroidal compounds that give the herb its effect on the stress response. A standardised extract is adjusted so each dose contains a defined percentage of these compounds, which is what lets a product be dosed repeatably and compared to a clinical trial. Generic non-standardised root powder does not do this, which is why it has no clinical basis for a specific dose.
Three variables separate the branded extracts. The first is plant part: root-only versus root plus leaf. This matters because leaf material carries more withaferin A, a particularly active withanolide with a different biological profile from the root compounds. The second is the standardisation level, the headline percentage on the label. The third is the resulting dose, because a more concentrated extract delivers its actives in a smaller capsule.
The crucial thing to hold onto is that these three variables interact. A higher percentage is not simply "stronger", because it usually comes paired with a different plant part and a different dose. That is why the extracts are not interchangeable milligram for milligram, and why the sensible way to choose is by matching the extract to the trials that used it.
KSM-66 is a full-spectrum, root-only ashwagandha extract standardised to a minimum of around 5% withanolides, produced with a process designed to preserve a broad compound profile rather than isolate a single marker. Of the three, it has the most published human randomised controlled trials behind it, and the bulk of that evidence sits in stress, cortisol and sleep.
The most cited trial is Chandrasekhar and colleagues (2012), in which chronically stressed adults took KSM-66 at 300 mg twice daily for 60 days and showed a substantial reduction in serum cortisol and in stress questionnaire scores versus placebo [1]. A 2019 trial by Salve and colleagues reproduced anxiolytic and cortisol-lowering effects at similar doses in healthy but stressed adults [2]. This is the evidence base that gives ashwagandha its reputation as a stress herb, and it is largely KSM-66 evidence.
None of this makes KSM-66 a miracle, and the wider picture keeps it honest. Recent independent syntheses and the NCCIH position grade ashwagandha''s stress evidence as moderate rather than strong, noting that older reviews conflict and that anxiety findings specifically are less clear [5]. So the fair statement is: KSM-66 is the most studied ashwagandha extract for stress and sleep, and ashwagandha''s stress evidence overall is moderate. It is the sensible default when those are your goals, precisely because your product then matches the trials.
Sensoril is made from both root and leaf and is standardised to a higher withanolide content (a minimum of around 10%) plus a defined level of glycowithanolides. Including the leaf shifts the compound profile, notably raising withaferin A, and Sensoril is typically dosed lower than KSM-66, often in the region of 125 to 300 mg per day.
Its published evidence leans toward cognition and mood rather than the cortisol-and-stress focus of the KSM-66 literature. A 2017 trial by Choudhary and colleagues gave Sensoril to adults over eight weeks and reported improvements across memory, executive function, attention and processing speed on neuropsychological testing [3]. That is a genuine and specific trial base, and it is why Sensoril is often the extract chosen when the goal is cognitive support rather than stress relief.
The honest caveat is that ashwagandha''s cognition evidence is thinner and less replicated than its stress evidence, and the NCCIH considers the cognition and mood applications less well established than the stress use [5]. Sensoril''s distinction is therefore less "the stronger extract" and more "the extract whose published trials match a cognitive goal". If that is your priority, that alignment is a reasonable basis to choose it.
Shoden is the most recent of the three and the most concentrated, standardised to a very high level of withanolide glycosides (around 35%). That concentration is what allows its notably small daily dose, often around 120 mg, since the active compounds are delivered in a fraction of the material.
Its main published human evidence is in sleep. A randomised placebo-controlled trial by Deshpande and colleagues (2020) reported improvements in sleep quality with Shoden over several weeks [4]. That is a real signal, but it is a small literature: Shoden is the least studied of the three overall, so despite carrying the highest headline percentage it has the thinnest independent track record.
This is the clearest illustration of why the label number can mislead. Shoden''s 35% dwarfs KSM-66''s 5%, yet KSM-66 has many times the published trials. A high concentration is a formulation achievement, not a substitute for an evidence base. Shoden is a reasonable choice for someone specifically drawn to its low-dose sleep positioning, provided they understand they are choosing the least-studied of the three.
| Feature | KSM-66 | Sensoril | Shoden | |---|---|---|---| | Plant part | Root only | Root and leaf | Root and leaf (concentrated) | | Standardisation | ~5% withanolides | ~10% withanolides plus glycowithanolides | ~35% withanolide glycosides | | Typical daily dose | 300 to 600 mg | ~125 to 300 mg | ~120 mg | | Main published evidence | Stress, cortisol, sleep | Cognition, mood | Sleep | | Depth of trial base | Deepest | Moderate | Thinnest | | Best matched to | Stress and sleep goals | Cognitive and mood goals | Low-dose sleep positioning |
The single most important row is the last two. There are no head-to-head trials pitting these extracts against each other, so no one can honestly claim a proven winner. What differs is which trial base sits behind each, and the sensible reading is to match the extract to the outcome its studies actually measured. Every one of them beats generic non-standardised powder for predictable dosing, because at least you know what is in the capsule.
Here is how to turn that into a purchase.
Decide your goal first. For stress, cortisol and sleep, KSM-66 is the most evidence-aligned choice, because that is where its deep trial base lives [1][2]. For cognition and mood, Sensoril''s published studies are the better match [3]. For a small-dose sleep product, Shoden is a defensible pick, with the clear understanding that it is the least studied [4].
Match the dose to the extract, not to a generic number. KSM-66 trials cluster around 300 to 600 mg per day, often split; Sensoril studies sit lower; Shoden is used at roughly 120 mg because of its concentration. Copying one extract''s dose onto another is a mistake, because they are not equivalent milligram for milligram.
Give it time. Sleep effects sometimes appear within two to three weeks, but the stress and cortisol changes seen in trials emerge nearer 60 days. Judge any of these extracts over about eight weeks, not a few days.
And avoid the label trap. The highest withanolide percentage does not crown the strongest product. Read it as one specification among several, and let the trial base, not the number, guide you.
The contraindications belong to ashwagandha itself, not to any one brand, and they are not optional. All three extracts sit under the same cautions.
Ashwagandha carries a recognised, mostly mild liver signal (a LiverTox likelihood score of B), with rare more serious cases, so it should be avoided in cirrhosis or advanced liver disease and stopped if signs of liver trouble appear [6]. It is contraindicated in pregnancy and breastfeeding [5][6]. Because it is immunomodulatory and affects thyroid hormones, it is not recommended in autoimmune conditions or hyperthyroidism, and it warrants caution and monitoring for anyone on thyroid medication [5]. It should be paused before surgery and used cautiously with hormone-sensitive prostate cancer [5].
Interaction cautions include sedatives (additive drowsiness), thyroid medicines (potentiation), immunosuppressants (opposing effects), seizure medicines, diabetes and blood pressure medicines [5]. Leaf-containing extracts (Sensoril, Shoden) carry more withaferin A, which is more biologically active, so in principle profile differences exist between the extracts, but the practical contraindications above apply to all of them.
Pregnant, breastfeeding, or on medication? Check with a healthcare professional first.
We would rather help you buy the product the evidence studied than sell you the biggest number on a shelf. That is the whole point of separating KSM-66, Sensoril and Shoden instead of treating "ashwagandha" as one undifferentiated thing.
Our own ashwagandha stress tonic is built around the herb''s best-evidenced use, the gradual, cortisol-modulating stress-and-sleep effect that the KSM-66 trial base describes, and we present that grade as it is: moderate, time-dependent, and no substitute for the lifestyle changes that lower a chronic stress load in the first place. If your goal is cognition or a low-dose sleep product instead, we will point you to the extract whose trials match, rather than pretend one tub does everything.
For the fuller picture, our complete ashwagandha guide and the wider Remedy Library carry the same rule: name the extract, name the dose, name the grade. That is how you choose ashwagandha well.
1. Chandrasekhar K, et al. (2012). A prospective, randomised double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety (KSM-66). Indian Journal of Psychological Medicine. Large reduction in serum cortisol and stress scores over 60 days. 2. Salve J, et al. (2019). Adaptogenic and anxiolytic effects of ashwagandha root extract in healthy adults (KSM-66). Cureus. Reduced anxiety and cortisol versus placebo. 3. Choudhary D, et al. (2017). Efficacy and safety of ashwagandha root extract in improving memory and cognitive functions (Sensoril). Journal of Dietary Supplements. Improvements across memory, executive function and attention over eight weeks. 4. Deshpande A, et al. (2020). A randomised, double-blind, placebo-controlled study to evaluate the effects of ashwagandha extract on sleep quality (Shoden). Sleep Medicine. Reported improvement in sleep quality; small trial base for this extract. 5. National Center for Complementary and Integrative Health (2023). Ashwagandha. Government evidence synthesis; grades stress evidence moderate, cognition and anxiety less clear, and lists contraindications and interactions. 6. NIH LiverTox (2023). Ashwagandha (NBK548536). Likelihood score B for clinically apparent liver injury; mostly mild and self-limiting, rare severe cases, avoid in advanced liver disease.
There is no head-to-head trial declaring a winner, so "best" depends on your goal and which evidence base you want behind it. KSM-66 has the deepest human trial record, mostly for stress, cortisol and sleep, and is a sensible default for those uses. Sensoril, standardised higher and including leaf, is studied more for cognition and mood at a lower dose. Shoden is newer, highly concentrated and used at a small dose, with a smaller but growing sleep literature. All three are standardised, which already puts them ahead of generic non-standardised root powder that has no clinical basis for specific dosing.
Mainly the plant material and the standardisation. KSM-66 is root-only and standardised to around 5% withanolides, produced to preserve a broad compound profile, and it carries the most published stress and sleep trials. Sensoril uses both root and leaf and is standardised to a higher withanolide content plus glycowithanolides, which shifts the compound profile (including more withaferin A) and is typically dosed lower. In practice KSM-66 is the more common choice for stress and sleep, Sensoril for cognition and mood.
Shoden is a more recent branded ashwagandha extract standardised to a very high level of withanolide glycosides (around 35%), which allows a much smaller daily dose than KSM-66 or Sensoril. Its main published human evidence is in sleep, where a small number of trials report improvements in sleep quality. It is the least studied of the three overall, so it has the thinnest independent track record even though the concentration on the label is the highest.
Not straightforwardly. A higher percentage lets a manufacturer deliver the active compounds in a smaller capsule, but it does not automatically mean a better clinical result, because the extracts also differ in plant part and compound profile. Withaferin A, more concentrated in leaf-containing extracts, behaves differently from the root withanolides. The percentage is one variable among several, and clinical outcomes depend on the specific extract studied at a specific dose, not on the headline number alone.
Clinical trials of standardised extracts typically use 300 to 600 mg per day of KSM-66, often split into two doses, over at least 60 days for stress and cortisol outcomes. Sensoril is commonly studied around 125 to 300 mg per day, and Shoden at roughly 120 mg per day because of its high concentration. The right dose is the one matched to the specific extract, since they are not interchangeable milligram for milligram.
Sleep-related effects are sometimes reported within two to three weeks, but the stress and cortisol changes measured in trials tend to emerge around 60 days. Two weeks is not a fair assessment window for the stress-resilience effect. This is true across the extracts: ashwagandha is a gradual-onset herb, not a same-day one.
The safety profile is broadly the herb''s profile rather than the brand''s. All ashwagandha carries a recognised, mostly mild liver signal, contraindications in pregnancy, thyroid disease and autoimmune conditions, and interaction cautions with sedatives, thyroid and immune medicines. Leaf-containing extracts contain more withaferin A, which is more biologically active, so in principle profile differences exist, but the contraindications apply to all three and should be respected regardless of brand.
KSM-66 is the most defensible choice for those two goals, simply because it carries the deepest published trial base for stress, cortisol and sleep at the doses people actually use. That is not proof it outperforms the others in a head-to-head, because no such trial exists, but it means your product is backed by the most relevant evidence. Expect a gradual effect judged over about eight weeks rather than a same-week change, and respect the contraindications, which apply whichever brand you pick.
It might. Sensoril, which includes leaf material and is standardised higher, has more of its published evidence in cognition and mood, usually at a lower dose than KSM-66. If that is your priority, choosing the extract whose trials match your goal is a reasonable way to decide. The honest caveat is that ashwagandha''s cognition evidence is thinner than its stress evidence overall, so keep expectations modest whichever extract you choose.
Probably not for specific dosing. Generic non-standardised root powder does not declare a withanolide content, so you cannot know how much active compound you are getting, and it has no clinical trial basis for a specific dose the way the branded standardised extracts do. It is not necessarily useless, but it is a different, less predictable product. If you are choosing ashwagandha for a specific outcome, a standardised extract is the more evidence-aligned pick.